Insider Selling: West Pharmaceutical Services (NYSE:WST) VP Sells $921,260.00 in Stock

Posted by Francis Steltz on Sep 15th, 2026

West Pharmaceutical Services, Inc. (NYSE:WST – Get Free Report) VP Annette Favorite sold 2,524 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $365.00, for a total transaction of $921,260.00. Following the completion of the sale, the vice president directly owned 21,818 shares of the company’s stock, valued at approximately $7,963,570. This represents a 10.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

West Pharmaceutical Services Trading Up 2.6%

Shares of WST traded up $9.16 during trading hours on Tuesday, hitting $364.36. 960,006 shares of the stock traded hands, compared to its average volume of 840,040. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $386.00. The firm has a market capitalization of $25.64 billion, a PE ratio of 46.65, a price-to-earnings-growth ratio of 2.42 and a beta of 1.14. The business has a fifty day moving average of $348.42 and a 200-day moving average of $311.52.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company had revenue of $872.30 million during the quarter, compared to analysts’ expectations of $839.98 million. During the same quarter in the previous year, the company earned $1.84 EPS. West Pharmaceutical Services’s revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Analysts expect that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were given a $0.22 dividend. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio is currently 11.27%.

Hedge Funds Weigh In On West Pharmaceutical Services

Large investors have recently bought and sold shares of the company. Greenleaf Trust raised its holdings in West Pharmaceutical Services by 4.1% in the 2nd quarter. Greenleaf Trust now owns 843 shares of the medical instruments supplier’s stock valued at $303,000 after buying an additional 33 shares during the last quarter. Wealth Alliance LLC increased its holdings in shares of West Pharmaceutical Services by 3.8% during the first quarter. Wealth Alliance LLC now owns 945 shares of the medical instruments supplier’s stock valued at $237,000 after acquiring an additional 35 shares in the last quarter. IFM Investors Pty Ltd lifted its position in West Pharmaceutical Services by 0.3% in the 1st quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock valued at $3,452,000 after acquiring an additional 43 shares in the last quarter. Compound Planning Inc. boosted its holdings in West Pharmaceutical Services by 3.6% during the 1st quarter. Compound Planning Inc. now owns 1,224 shares of the medical instruments supplier’s stock worth $307,000 after acquiring an additional 43 shares during the last quarter. Finally, Cornerstone Planning Group LLC grew its holdings in shares of West Pharmaceutical Services by 90.9% in the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 50 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

WST has been the subject of a number of research analyst reports. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. BNP Paribas Exane initiated coverage on West Pharmaceutical Services in a research note on Monday, July 13th. They issued an “outperform” rating and a $447.00 price objective on the stock. Zacks Research downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. Barclays raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. Finally, Wolfe Research started coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They set an “outperform” rating and a $375.00 target price on the stock. Eleven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $379.08.

Read Our Latest Research Report on WST

West Pharmaceutical Services Company Profile

(Get Free Report)

West Pharmaceutical Services, Inc (NYSE: WST) develops and manufactures components and systems used to package, contain and deliver injectable medicines and other healthcare products. Its customers include pharmaceutical, biotechnology and medical device companies, which use West products in drug administration and medical applications.

The company’s offerings include elastomer components such as stoppers, plungers and seals; syringe and cartridge components; vial and container closure systems; and specialized delivery systems for injectable and other complex medicines.